Immunome, Inc. (IMNM) Stock Price

IMNMStock

$29.39+171.94%52W

Market Cap$3.34B

P/E—

PEG Ratio—

Div yield—

Beta2.53

IMNM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)16.13%

Price vs S&P 500 (4W)17.58%

VGM Score34.48

Book Value / Share (Quarterly)$5.20

P/TBV (Annual)20.53x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.90

Price vs S&P 500 (YTD)18.44%

Net Profit Margin (TTM)-1687.08%

EPS (TTM)$-2.36

10-Day Avg Trading Volume1.25M

EPS Excl Extra (TTM)$-2.36

EPS (Annual)$-2.43

ROI (Annual)-33.48%

Cash / Share (Quarterly)$5.15

ROA (Last FY)-31.09%

Revenue Growth TTM (YoY)-63.29%

EBITD / Share (TTM)$-2.47

ROE (5Y Avg)-111.44%

Operating Margin (TTM)-1784.14%

Cash Flow / Share (Annual)$-1.83

P/B Ratio5.10x

P/B Ratio (Quarterly)4.20x

Net Income / Employee (Annual)$-1,815,300

EV / Revenue (TTM)192.07x

Net Interest Coverage (TTM)-2470.00x

ROA (TTM)-47.32%

EPS Incl Extra (Annual)$-2.43

Current Ratio (Annual)14.69x

Quick Ratio (Quarterly)21.26x

3-Month Avg Trading Volume1.26M

52-Week Price Return171.94%

Revenue / Employee (TTM)$34,300

Tangible BV / Share (Quarterly)$0.50

P/S Ratio (Annual)432.32x

Asset Turnover (Annual)0.01x

52-Week High$30.06

EPS Excl Extra (Annual)$-2.43

CapEx CAGR (5Y)93.32%

26-Week Price Return27.38%

Quick Ratio (Annual)14.53x

13-Week Price Return21.99%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.68x

Enterprise Value$2.42B

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)7.59%

Revenue / Employee (Annual)$59,300

Pretax Margin (Annual)-3059.99%

Cash / Share (Annual)$5.78

3-Month Return Std Dev53.76%

Net Income / Employee (TTM)$-1,919,600

ROE (Last FY)-33.48%

Net Interest Coverage (Annual)-784.00x

EPS Basic Excl Extra (Annual)$-2.43

P/FCF (TTM)128.80x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.36

ROI (TTM)-51.15%

P/S Ratio (TTM)238.36x

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$1.37

Price vs S&P 500 (52W)153.63%

Year-to-Date Return30.40%

5-Day Price Return1.63%

EPS Normalized (Annual)$-2.43

ROA (5Y Avg)-84.20%

Net Profit Margin (Annual)-3059.99%

Month-to-Date Return23.07%

Cash Flow / Share (TTM)$-1.77

EBITD / Share (Annual)$-2.54

Operating Margin (Annual)-3228.83%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-111.44%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.36

P/TBV (Quarterly)56.26x

P/B Ratio (Annual)3.74x

Pretax Margin (TTM)-1687.08%

Book Value / Share (Annual)$5.61

Price vs S&P 500 (13W)19.20%

Beta2.53x

Revenue / Share (TTM)$0.04

ROE (TTM)-51.15%

52-Week Low$8.66

vGradeF

gGradeF

mGradeB

vgmGradeD

IMNM Earnings Surprise History

Q2 25-0.50est. -0.50

Q3 25-0.65est. -0.54

Q4 25-0.76est. -0.57

Q2 26-0.65est. -0.50

IMNM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.24

4.20

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMNMImmunome, Inc.	F	F	B	$29.39
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Immunome, Inc.

Immunome Inc is a targeted oncology company advancing antibody-drug conjugates and radioligand therapies. Its lead program, varegacestat, demonstrated positive Phase 3 results in desmoid tumors, with additional programs including the Phase 1-stage ROR1 ADC IM-1021 and IND-cleared FAP-targeted radioligand IM-3050. The company maintains a preclinical portfolio of solid tumor ADCs.